Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Paper Canadian currency of various denominations
Tech Stocks

TFSA: Top Canadian Stocks for Big Tax-Free Capital Gains

The real magic of a TFSA happens when quality growth stocks can grow and multiply.

Read more »

diversification and asset allocation are crucial investing concepts
Stocks for Beginners

The 3 Stocks I’d Buy and Hold Into 2026

Strong earnings momentum and clear growth plans make these Canadian stocks worth considering in 2026.

Read more »

chatting concept
Dividend Stocks

BCE vs. Telus: Which TSX Dividend Stock Is a Better Buy in 2026?

Down almost 50% from all-time highs, Telus and BCE are two TSX telecom stocks that offer you a tasty dividend…

Read more »

pig shows concept of sustainable investing
Dividend Stocks

Your 2026 TFSA Game Plan: How to Turn the New Contribution Room Into Monthly Cash

With the 2026 TFSA limit at $7,000, a simple “set-and-reinvest” plan using cash-generating dividend staples like ENB, FTS, and PPL…

Read more »

Business success of growth metaverse finance and investment profit graph concept or development analysis progress chart on financial market achievement strategy background with increase hand diagram
Dividend Stocks

Want $252 in Super-Safe Monthly Dividends? Invest $41,500 in These 2 Ultra-High-Yield Stocks

Discover how to achieve a high yield with trusted stocks providing regular payments. Invest smartly for a steady income today.

Read more »

Hourglass and stock price chart
Energy Stocks

Two High-Yield Dividend Stocks You Can Buy and Hold for a Decade

These companies have increased their dividends annually for decades.

Read more »

Piggy bank and Canadian coins
Dividend Stocks

Canadians: Here’s How Much You Need in Your TFSA to Retire

If you hold Fortis Inc (TSX:FTS) stock in a TFSA, you might earn enough dividends to cover part of your…

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Investing

TFSA Season is Here: Canadian Stocks Worth Holding Tax-Free All Year

Investors should focus on total returns in their TFSA whether their focus is on income, growth, or a combination of…

Read more »